Current and Future Gastroesophageal Cancer Treatments
Current and Future Gastroesophageal Cancer Treatments
On-demand webinar, slides and e-learning for HCPs with an interest in gastric and gastroesophageal cancer
On-demand webinar, slides and e-learning for HCPs with an interest in gastric and gastroesophageal cancer
Dr. Yelena Janjigian, Dr Elizabeth Smyth, Dr. Samuel J Klempner
In this 4-part on-demand webinar, leading medical experts from the US and UK come together to discuss the current gastroesophageal cancer treatment landscape and near-future developments.
Watch the videos, download the slides and access the e-learning using the blue button below the videos.
- The discussion opens with an overview of gastric and gastroesophageal cancer from Dr Yelena Janjigian
- Dr Sam Klempner and Dr Lizzy Smyth present case studies outlining treatment, biomarker selection and adverse event management for localised and metastatic disease
- Experts engage in an insightful panel discussion and answer pressing questions
Would you make the same clinical decisions as your peers?
Find out by watching the interactive case-based discussion and downloading the accompanying slides below, then take the e-learning to earn a CME credit.
Overview of Gastroesophageal Cancer
Video |
23 min
|
Apr 2023
I agree that this educational programme:
Non-metastatic Gastroesophageal Cancers
Video |
20 min
|
Apr 2023
I agree that this educational programme:
Metastatic Gastroesophageal Cancers
Video |
19 min
|
Apr 2023
I agree that this educational programme:
Panel Discussion and Summary
Video |
11 min
|
Apr 2023
I agree that this educational programme:
Clinical Takeaways
-
The treatment landscape of gastric and gastroesophageal cancer is evolving for both localised and metastatic disease
-
In the first-line localised disease, new data is expected for the pre-operative setting. Anti-CLDN 18.2 strategies are a key player for first-line advanced disease, and approval is anticipated
-
In the later-line metastatic setting, more anti-angiogenic treatments are a potential option, and new data is awaited
-
Biomarker testing plays a key role in treatment selection strategies, and therefore testing for HER2, MSI, PD-L1, and recently CLDN 18.2 should always be considered
This educational programme is supported by an Independent Medical Education Grant from Bayer
GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.
Other programmes of interest
Other programmes developed by Dr. Samuel J Klempner

Dr. Samuel J Klempner
GI Medical Oncologist
Massachusetts General Hospital
United States (US)